Bladder cancer risk in users of selected drugs for cardiovascular disease prevention by V. Guercio et al.
Cancer Causes & Control
 
BLADDER CANCER RISK IN USERS OF SELECTED DRUGS FOR
CARDIOVASCULAR DISEASE PREVENTION
--Manuscript Draft--
 
Manuscript Number:
Full Title: BLADDER CANCER RISK IN USERS OF SELECTED DRUGS FOR
CARDIOVASCULAR DISEASE PREVENTION
Article Type: Original Article
Keywords: aspirin;  calcium channel blockers;  case-control study;  bladder cancer;  risk factor;
statins.
Corresponding Author: Valentina Guercio
Universita degli Studi di Milano
Milano, ITALY
Corresponding Author Secondary
Information:
Corresponding Author's Institution: Universita degli Studi di Milano
Corresponding Author's Secondary
Institution:
First Author: Valentina Guercio
First Author Secondary Information:
Order of Authors: Valentina Guercio
Federica Turati
Cristina Bosetti
Jerry Polesel
Diego Serraino
Maurizio Montella
Massimo Libra
Antonio Galfano
Carlo La Vecchia
Alessandra Tavani
Order of Authors Secondary Information:
Funding Information: Fondazione Italiana per la Ricerca sul
Cancro (FIRC)
Not applicable
Abstract: Purpose: To investigate the relation between bladder cancer risk and the use of
selected drugs for cardiovascular disease (CVD) prevention, such as aspirin, statins
and calcium channel blockers (CCBs).
Methods: We analyzed data from a multicentric case-control study conducted in Italy
between 2003 and 2014, including 690 bladder cancer cases and 665 hospital
controls. Odds ratios (OR) of bladder cancer and corresponding 95% confidence
intervals (CI) were estimated using unconditional multiple logistic regression models.
Results: The ORs for bladder cancer were 1.21 (95% CI 0.87-1.68) for regular use of
aspirin, 0.72 (95% CI 0.54-0.97) for use of any CCBs, and 1.32 (95% CI 0.87-1.99) for
use of any statins. A slight inverse association was found with duration of use of CCBs,
while no consistent association was found with duration of use, age at first use and
frequency for aspirin and statins use and, further, with indication of use for aspirin (as
analgesic or for cardiovascular disease prevention) for aspirin. No significant
association was found for use of various combinations of drugs, or for use of all drugs
combined (OR of 1.23, 95% CI 0.31-4.85).
Powered by Editorial Manager® and ProduXion Manager® from Aries Systems Corporation
Conclusions: Our data indicate the lack of a relevant association between use of
selected drugs for CVD prevention and bladder cancer risk, and suggest a potential
favourable role for CCBs.
Suggested Reviewers: Fabio Levi
fabio.levi@chuv.ch
Antonia Trichopoulou
 antonia@nut.uoa.gr
Esteve Fernandez
efernandez@iconcologia.net
Powered by Editorial Manager® and ProduXion Manager® from Aries Systems Corporation
1 
 
Bladder cancer risk in users of selected drugs for cardiovascular disease prevention  
 
Guercio V1, Turati F1,2,  Bosetti C3, Polesel J4, Serraino D4, Montella M5, Libra M6, Galfano A7,  La Vecchia C1, 
Tavani A3   
 
1Department of Clinical Sciences and Community Health, Università degli Studi di Milano, Milan, Italy. 
2 Department of Medical Statistics, Biometry and Bioinformatics, Fondazione IRCCS Istituto Nazionale Tumori, 
Milan; Italy 
3Department of Epidemiology, IRCCS-Istituto di Ricerche Farmacologiche “Mario Negri”, Milan; Italy. 
4Unit of Cancer Epidemiology, CRO Aviano National Cancer Institute, Aviano, Italy;  
5 Unit of Epidemiology, Istituto Tumori “Fondazione Pascale IRCCS”, Naples; Italy 
6 Department of Biomedical and Biotechnological Sciences, Laboratory of Translational Oncology and 
Functional Genomics, Section of General and Clinical Pathology and Oncology, Università di Catania, Catania; 
Italy 
7 Department of Urology, Ospedale Niguarda Ca' Granda, Milan; Italy 
 
Correspondence to: Guercio Valentina, PhD 
Department of Clinical Sciences and Community Health, Università degli Studi di 
Milano, Milan, Italy 
Tel. +39-0250320873; fax: +39-0250320866 
E-mail: valentina.guercio@unimi.it 
 
 
  
Conflicts of Interest and Source of Funding 
This work was conducted with the contribution of the Fondazione Italiana per la Ricerca sul Cancro (FIRC). F.T. 
was support by a fellowship from the FIRC till May 2016.  
Authors declare no conflicts of interest
Manuscript Click here to download Manuscript Manuscript.doc 
Click here to view linked References
2 
 
ABSTRACT 
Purpose: To investigate the relation between bladder cancer risk and the use of selected drugs for cardiovascular 
disease (CVD) prevention, such as aspirin, statins and calcium channel blockers (CCBs). 
Methods: We analyzed data from a multicentric case-control study conducted in Italy between 2003 and 2014, 
including 690 bladder cancer cases and 665 hospital controls. Odds ratios (OR) of bladder cancer and 
corresponding 95% confidence intervals (CI) were estimated using unconditional multiple logistic regression 
models.  
Results: The ORs for bladder cancer were 1.21 (95% CI 0.87-1.68) for regular use of aspirin, 0.72 (95% CI 
0.54-0.97) for use of any CCBs, and 1.32 (95% CI 0.87-1.99) for use of any statins. A slight inverse association 
was found with duration of use of CCBs, while no consistent association was found with duration of use, age at 
first use and frequency for aspirin and statins use and, further, with indication of use for aspirin (as analgesic or 
for cardiovascular disease prevention) for aspirin. No significant association was found for use of various 
combinations of drugs, or for use of all drugs combined (OR of 1.23, 95% CI 0.31-4.85).   
Conclusions: Our data indicate the lack of a relevant association between use of selected drugs for CVD 
prevention and bladder cancer risk, and suggest a potential favourable role for CCBs. 
 
KEYWORDS: aspirin; calcium channel blockers; case-control study; bladder cancer; risk factor; statins
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INTRODUCTION 
With the progressive aging of the population, drugs for primary prevention of cardiovascular disease 
(CVD) are increasingly prescribed. These include mostly anti-hypertensives, aspirin and statins, frequently used 
in association. However, their action on carcinogenesis, particularly on the bladder, is not fully understood when 
used alone or in various combinations.  Aspirin use, due to its anti-inflammatory properties, has been inversely 
related to the risk of various common cancers, including those of the colorectum, oesophagus, stomach, breast, 
and prostate (1, 2). Statins have anticancer activities in ‘in vivo’ and ‘in vitro’ studies (3), and meta-analyses of 
epidemiological studies showed statistically significant reductions of haematological malignancies (4) and 
prostate cancer (5), and a non significant decreased risk of lung (6), breast (7) and kidney (8) cancers. However, 
a recent combined analysis of randomized trials showed no material effect of statin on cancer risk (9). Only a 
few studies have been conducted on the association between antihypertensive agents and cancer risk. Current use 
of any antihypertensive agents- such as ACE inhibitors, β-blockers, calcium channel blockers (CCBs)-  has been 
associated with a higher risk of breast cancer, with no relation with duration (10). 
Specifically for bladder cancer risk, several epidemiological studies have considered the relation with aspirin 
with inconsistent results, ranging from null (11, 12), to direct (13) or inverse (14) associations. Two recent meta-
analyses pooling such results found an overall null association (15, 16). Two other meta-analyses on statin use 
and bladder cancer risk indicated no increased risk among users (17, 18). The relation between any 
antihypertensive agents and bladder cancer risk was investigated in an US population case-control study 
reporting null results (19).  
Since control and prevention of CVD generally involves the use of multiple drugs, drug interactions should also 
be considered. Particularly, statins are metabolized by the cytochrome P450 3A4 to more water-soluble 
metabolites excreted in either bile and urine. Drugs inhibiting cytochrome P450 3A4 activity, such as CCBs 
(verapamil, diltiazem and mibefradil), might increase plasma statin levels. 
The aim of this paper is to provide further data on the association between use of selected drugs for CVD 
prevention and bladder cancer risk using data from a case–control study conducted in Italy between 2003 and 
2014.
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MATERIALS AND METHODS 
A case-control study on bladder cancer was conducted between 2003 and 2014 within an established Italian 
network of collaborating centres, including Aviano (Pordenone) and Milan in northern Italy, and Naples and 
Catania in southern Italy (20, 21). Cases were 690 patients (595 men and 95 women, median age 67 years; range 
25-84 years) with incident transitional cell carcinoma of the bladder cancer admitted to major general hospitals 
in the study areas. Nearly all bladder cancers were confirmed by histological testing on tumour tissue specimen 
from biopsy or surgery, and three cases were confirmed by cytology only. Controls were subjects admitted to the 
same hospitals as cases for a wide spectrum of acute, non-neoplastic conditions, not related to smoking or other 
known or likely risk factors for bladder cancer. The control group included 690 patients frequency-matched to 
cases by study centre, sex and 5-year age group. Twenty-five controls were excluded after enrolment because of 
inappropriate admission diagnosis, thus leaving 665 eligible controls (561 men and 104 women; median age 66 
years; range 27-84 years). Overall, 28.9% of controls were admitted for traumas, 22.1% for non-traumatic 
orthopaedic disorders, 39.3% for acute surgical conditions, and 9.8% for miscellaneous other illnesses. All study 
subjects signed an informed consent, according to the recommendations of the Board of Ethics of the study 
hospitals. The proportion of refusal among cases and controls approached was less than 5%. 
All participants were interviewed during their hospital stay using a structured questionnaire including 
information on sociodemographic characteristics, anthropometric measures, selected lifestyle and dietary habits 
(including tobacco smoking and alcohol drinking), a personal history of selected diseases and drug use, and 
family history of cancer. Information on use of aspirin, CCBs and statins included age at first use, frequency and 
duration of use. Indication for use of aspirin (i.e., analgesic or CVD prevention) was also recorded. Regular use 
was defined as use at least once a week for more than 6 months. Comprehensive lists of the main preparations in 
Italy containing aspirin (any medication containing acetyl salicylic acid), CCBs or statins were supplied to 
facilitate recall. 
Odds ratios (ORs) of bladder cancer and the corresponding 95% confidence intervals (CIs) according to the 
use of aspirin, CCBs and statins were estimated using unconditional multiple logistic regression models adjusted 
for age, sex, study centre, year of interview, education, tobacco smoking and diabetes. Additional models 
including further terms for alcohol consumption, body mass index, family history of bladder cancer and history 
of cystitis did not substantially changed the OR, and therefore these covariates were not included in the final 
models. ORs of bladder cancer for use of various combinations of the three classes of medications were also 
estimated.
5 
 
RESULTS 
Table 1 provides the distribution of bladder cancer cases and controls according to selected variables. By 
design, cases and controls had a similar distribution by study centre, sex, and age. The two groups were also 
similar in terms of education, whereas current and heavy tobacco smoking was more frequent among cases than 
controls. 
Table 2 shows ORs and 95% CIs of bladder cancer with various measures of use of aspirin, CCBs and 
statins. A total of 125 cases (18.1%) and 84 controls (12.6%) reported regular use of aspirin, corresponding to an 
adjusted OR of 1.21 (95% CI 0.87-1.68). The ORs were 1.19 (95% CI 0.75-1.87) for  <5  and 1.20 (95% CI 
0.78-1.84) for >5 years of use and 1.26, (95% CI 0.79-2.02) for patients starting use when aged <60 years  and 
1.15 (95% CI 0.75-1.75) at age ≥60 years. The ORs were 0.64 (95% CI 0.28-1.46) for use <7 and 1.35 (95% CI 
0.95-1.92) for >7 times per week, and 0.95 (95% CI 0.39-2.32) for use as an analgesic and 1.29 (95% CI 0.91-
1.83) for CVD prevention. As for CCBs, the ORs were 0.72 (95% CI 0.54-0.97) for regular  compared with non 
regular use. The ORs were 0.96 (95% CI 0.64-1.43) for use <7 years and 0.55 (95% CI 0.37-0.82) for use >7 
years, 0.55 (95% CI 0.37-0.83) in patients starting use when aged <60 years and 0.93 (95% CI 0.63-1.37) in 
those starting after, and 0.46 (95% CI 0.20-1.06) for <7 and 0.76 (95% CI 0.56-1.04) for >7 times per week. For 
regular versus never use of statins the OR was 1.32 (95% CI, 0.87-1.99); the OR was lower for <5 year use (OR 
0.88, 95% CI 0.48-1.62) than for >5 years (OR 1.91, 95% CI 1.09-3.35), and the ORs were 1.83 (95% CI 0.98-
3.40) in patients starting use when aged <60 years and 1.05 (95% CI 0.61-1.79) >60 years, and 2.26 (95% CI 
0.46-11.1) for use <7  and 1.26 (95% CI 0.80-1.91) >7 times per week.  
Table 3 presents results for combined use of aspirin, any CCBs and any statins. None of the combination 
was significantly associated with bladder cancer risk, and compared to subjects who did not regularly use any of 
the three classes of medications; patients using all classes of drugs had an ORs of 1.23 (95% CI 0.31-4.85), 
although the estimate was based on 7 cases and 4 controls.
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DISCUSSION 
Data from this Italian study indicate that regular use of selected classes of drugs for CVD prevention (i.e. 
aspirin, CCBs and statins) doesn’t increase bladder cancer risk. The slightly non significant increased risk found 
for use of aspirin and statins was not supported by the dose- and duration relationships. The significantly 
decreased risk associated with CCB regular use was consistent with the inverse association with duration of use, 
but not with frequency of use.  
For aspirin use, no association was found also for high cumulative doses in a Spanish case-control study 
(22), for dose in a New England case-control study (11), for long duration of use (>11 years) in the same study 
and in the  Cancer  Prevention  Study  II  Nutrition   
Cohort (>5 years) (23), and for dose and frequency of use in the The Health Professionals Follow-Up Study 
(24). Moreover, a large-scale, long-term trial based on data from the Women’s Health Study showed that low-
dose aspiring use (100 mg/day) for an average 10 years did not reduce the incidence of bladder cancer (25). 
Thus, overall evidence indicates a lack of role of aspirin on bladder carcinogenesis. 
The relation of long-term statin use (mostly >5 years) and bladder cancer was considered in several 
randomized clinical trials, cohort and case-control studies finding mixed results. A meta-analysis of these studies 
reported an overall relative risk of 1.21 (95% CI 0.92-1.59) (18). Thus, although a few studies (26-28), including 
ours, found a slight increased risk, overall no association emerged and the issue needs to be further investigated. 
To our knowledge, this is the first epidemiological study evaluating the relation between the risk of bladder 
cancer in CCB users and in users of various combinations of aspirin, statins and CCBs. The inverse association 
with the dose- and duration of CCB use suggests a real favourable effect on bladder cancer risk. Preclinical 
studies in ‘in vitro’ and ‘in vivo’ have indicated that CCBs may be effective in blocking abnormal cell 
proliferation in several tumors (29). Anyway, the protective effect of CCB use and bladder cancer in humans 
needs to be further investigated. 
Although based on a relatively large sample size, our study included a small proportion of regular drug 
users, according to the reported pattern of aspirin use in Italy (30). Moreover, a limitation is that we had no 
information on the type of medication and the doses. Another possible limitation of our study is selection bias. 
However, cases and controls came from comparable catchment areas, and the participation rate was almost 
complete. Another potential limitation is that some of the diagnostic categories of the controls may be associated 
with increased drug use, mainly aspirin and/or other analgesics. However, the risk estimates did not change 
across the major diagnostic categories of controls, and patients admitted to hospital for CVD, and diseases 
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related with smoking were excluded. As for recall bias, hospital controls are preferable with reference to 
reliability and validity of information on drug use, as they are similarly sensitized towards various aspects of 
their medical history (31). Major confounding is also unlikely, because the risk estimates were adjusted for 
major risk factors of bladder cancer, mainly smoking, and further adjustment for many other variables did not 
modify the risk estimates.  
Thus, our findings, although based on few regular users of the selected drugs, are reassuring, suggesting a 
lack of relationship of aspirin and statins and a potential favourable effect of CCBs used for CVD prevention and 
bladder cancer risk. 
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Table 1. Distribution of 690 cases of bladder cancer and 665 controls according to centre, sex, age and other 
selected variables. Italy, 2003-2014. 
 
 
Cases Controls p valueb 
No. % No. % 
Centre      
Pordenone 242 35.1 250 37.6  
Milan 241 34.9 238 35.8  
Naples 129 18.7 100 15.0  
Catania 78 11.3 77 11.6 0.34 
Sex      
Men 595 86.2 561 84.4  
Women 95 13.8 104 15.6 0.33 
Age (years)      
< 60 148 21.5 178 26.8  
60-64 107 15.5 119 17.9  
65-69 164 23.8 147 22.1  
70-74 155 22.5 124 18.7  
≥ 75 116 16.8 97 14.6 0.06 
Education (years)a      
< 7 292 42.4 273 41.1  
7 - 11 224 32.5 215 32.3  
≥ 12 173 25.1 177 26.6 0.80 
Tobacco smokinga      
Never smokers 96 14.1 237 35.6  
Ex-smokers 310 45.5 284 42.7  
Current smokers      
< 15 cigarettes/day 79 11.6 53 8.0  
15-24 cigarettes/day 127 18.7 68 10.2  
≥ 25 cigarettes/day 69 10.1 23 3.5 <0.001 
Diabetes      
 No 578 83.8 608 91.4  
 Yes 112 16.2 57 8.6 <0.001 
aThe sum does not add up to the total because of some missing values.  
b p-value for association from χ2 statistic. 
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Table 2. Distribution of 690 bladder cancer cases and 665 controls, with corresponding odds ratio (OR) and 95% 
confidence interval (CI), according to aspirina, calcium channel blockers (CCBs)a and statina use. Italy, 2003–2014. 
 
Cases  
(%) 
Controls (%) ORb (95% CI) 
    
Aspirina use    
Non regular users 564 (81.9) 581 (87.4) 1.00c 
Regular users 125 (18.1) 84 (12.6) 1.21 (0.87-1.68) 
Duration of use (years)    
 <5 58 ( 8.4) 39 ( 5.9) 1.19 (0.75-1.87) 
 ≥5 65 ( 9.5) 45 ( 6.8) 1.20 (0.78-1.84) 
2-trend (p-value)   1.0  (0.3175) 
Age at first use (years)    
 <60 57 ( 8.3) 35 ( 5.3) 1.26 (0.79-2.02) 
 ≥60 67 ( 9.7) 49 ( 7.4) 1.15 (0.75-1.75) 
    
Frequency of use (times/week)     
 <7 13 ( 1.9) 14 ( 2.1) 0.64 (0.28-1.46) 
 ≥7 112 (16.3) 69 (10.4) 1.35 (0.95-1.92) 
2-trend (p-value)   2.3  (0.1287) 
Indication    
Analgesic 13 ( 1.9) 14 ( 2.1) 0.95 (0.39-2.32) 
Cardiovascular prevention 112 (16.3) 69 (10.4) 1.29 (0.91-1.83) 
    
CCB usea    
Non regular users 556  (80.8) 515  (77.4) 1.00c 
Regular users 132  (19.2) 150  (22.6) 0.72 (0.54-0.97) 
Duration of use (years)    
   <7 70   (10.2) 65   ( 9.8) 0.96 (0.64-1.43) 
    ≥7 60   ( 8.7) 83   (12.5) 0.55 (0.37-0.82) 
2-trend (p-value)   7.5  (0.0061) 
Age at first use (years)    
   <60 54   ( 7.8) 79   (11.9) 0.55 (0.37-0.83) 
    ≥60 78   (11.3) 71   (10.7) 0.93 (0.63-1.37) 
    
Frequency of use (times/week)    
   <7 12   ( 1.7) 15   ( 2.3) 0.46 (0.20-1.06) 
   ≥7 119  (17.3) 134  (20.2) 0.76 (0.56-1.04) 
2-trend (p-value)   3.4  (0.0640) 
    
Statin usea    
Non regular users 618  (89.7) 615  (92.5) 1.00c 
Regular users 71   (10.3) 50   ( 7.5) 1.32 (0.87-1.99) 
Duration of use (years)    
   <5 25   ( 3.6) 27   ( 4.1) 0.88 (0.48-1.62) 
   ≥5 46   ( 6.7) 22   ( 3.3) 1.91 (1.09-3.35) 
2-trend (p-value)   3.8  (0.0525) 
Age at first use (years)    
   <60 31   ( 4.5) 20   ( 3.0) 1.83 (0.98-3.40) 
   ≥60 40   ( 5.8) 29   ( 4.4) 1.05 (0.61-1.79) 
    
Frequency of use (times/week)    
   <7 8    ( 1.2) 2    ( 0.3) 2.26 (0.46-11.1) 
   ≥7 63   ( 9.1) 48   ( 7.2) 1.26 (0.82-1.94) 
2-trend (p-value)   1.4  (0.2315) 
 
a The sum does not add up to the total because of some missing values. b Estimated from multiple logistic regression 
model adjusted for age, sex, study centre, year of interview, education, tobacco smoking and diabetes. c Reference 
category.
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Table 3. Distribution of 690 bladder cancer cases and 665 controls, with corresponding odds ratio (OR) and 95% confidence interval (CI), according combined use of aspirina, 
calcium channel blockers (CCBs)a, and statinsa. Italy, 2003–2014. 
 Cases (%) Controls (%) ORb (95% CI) 
Combined use of aspirin, CCBs and statins    
   No 440  (64.0) 440  (66.2) 1.00c 
   Only aspirin 65   ( 9.4) 46   ( 6.9) 1.16 (0.75-1.79) 
   Only statins 29   ( 4.2) 18   ( 2.7) 1.59 (0.82-3.09) 
   Only CCBs 82   (11.9) 106  (15.9) 0.77 (0.54-1.10) 
   Aspirin + statins 22   ( 3.2) 11   ( 1.7) 1.90 (0.88-4.12) 
   Aspirin + CCBs 30   ( 4.4) 23   ( 3.5) 0.79 (0.43-1.45) 
   Statins + CCBs 13   ( 1.9) 17   ( 2.6) 0.59 (0.27-1.32) 
   All drugs 7    ( 1.0) 4    ( 0.6) 1.23 (0.31-4.85) 
    
a The sum does not add up to the total because of some missing values. 
b Estimated from multiple logistic regression model adjusted for age, sex, study centre, year of interview, education, tobacco smoking and diabetes. 
c Reference category. 
 
